Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction

Launched by BOEHRINGER INGELHEIM · Jun 24, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how well a medicine called Jardiance works and how safe it is for treating a type of heart failure where the heart’s pumping ability is weaker than normal, called heart failure with reduced ejection fraction (HFrEF). The study will compare patients starting Jardiance with those starting other commonly recommended heart failure medicines in a real-world setting in China. The main goal is to see if Jardiance helps reduce the chances of heart-related death or needing to be hospitalized for heart failure compared to these other treatments.

Adults aged 18 and older who have been diagnosed with this kind of heart failure, with specific signs showing their heart’s pumping function is low, may be eligible. Participants should be new users of either Jardiance or the other standard heart failure medicines and have certain test results that confirm their condition. If you join, your health will be followed over time to see how well the medicine works and if there are any side effects. It’s important to note that people who have already used similar drugs recently won’t be able to join. This study aims to help doctors understand which treatments might be best for heart failure patients in everyday medical practice.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • At least 18 years of age
• • Has at least 1 diagnosis of Heart Failure with Reduced Ejection Fraction (HFrEF) at baseline during the 6-month look-back period (on or prior to the index date)
• • Left Ventricular Ejection Fraction (LVEF) ≤40%
• • N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) \>125pg/mL or Brain Natriuretic Peptide (BNP)≥35 pg/mL
• • New users of Jardiance or guideline-recommended non-Sodium-glucose Cotransporter-2 inhibitors (SGLT2i) medications (Angiotensin-converting-enzyme inhibitors (ACEi)/Angiotensin II Receptor Blocker (ARB)/ Angiotensin Receptor-neprilysin Inhibitor (ARNI), beta-blockers, and Mineralocorticoid Receptor Antagonist (MRA)) for HFrEF, who had not used the respective index drug during the look-back period
• • Baseline data during the look-back period or on the index date have been collected
• • Body mass index (BMI) \<45 kg/m2
• Exclusion Criteria:
• • Patients treated with any SGLT-2i during the look-back period
• • Patients treated with any other SGLT-2i on the index date